ArticleJournal of contemporary brachytherapy2019
Analysis of local recurrence causes in uveal melanoma patients treated with
Article in Journal of contemporary brachytherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.Radiation oncology (London, England) · 2025Article
- Current Therapies and Potential Strategies for Uveal Melanoma.Drugs and drug candidates · 2025Article
- Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.Cancers · 2023Article
- Radiotherapy in Uveal Melanoma: A Review of Ocular Complications.Current oncology (Toronto, Ont.) · 2023Review
- Deterioration of Visual Acuity after Brachytherapy and Proton Therapy of Uveal Melanoma, and Methods of Counteracting This Complication Based on Recent Publications.Medicina (Kaunas, Lithuania) · 2023Review
- Ophthalmic applicator displacement as a method of treating large diffuse uveal melanomas.Journal of contemporary brachytherapy · 2023Article
- Intra-operative ocular ultrasonography of iodine-125 brachytherapy plaques in patients with uveal melanoma.Journal of contemporary brachytherapy · 2021Article
- Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height.Journal of contemporary brachytherapy · 2021Article
- The Value of Detecting and Monitoring ctDNA in Uveal Melanoma: Results of a Pilot Study and a Systematic Review.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo perform a retrospective analysis of factors which might affect the occurrence of a relapse of uveal melanoma after MATERIAL AND
methodsThe analysis concerned 343 patients treated in the years 2001-2012. The effect on local recurrence of such factors as patient's sex, age, tumour size, shape, pigmentation, location, presence of orange pigment or petechiae on tumour surface, retinal detachment, and blood or dispersed pigment in vitreous body were studied. Additional analysis concerned physical properties of brachytherapy (total dose, irradiation dose applied to tumour apex and base and irradiation time). Two groups of patients were distinguished: with and without a relapse. The diagnostic criterion for the relapse was growth of the tumour base or height by 0.5 mm.
resultsLocal recurrence of the uveal melanoma was observed in 29 patients (8.5%). Recurrences occurred with significantly higher frequency (
conclusionsTreatment of uveal melanomas with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.